Synapse - Find an Expert

352 Results

Serum chemokines and cytokines in CLL patients treated with duvelisib, an oral dual inhibitor of PI3K-delta, gamma

Meeting Abstract

Douglas, M.; Allen, K.; Sweeney, J.; O'Brien, S.; Flinn, I.; Horwitz, S.; Byrd, J.; Patel, M.; Kahl, B.; Foss, F.; more...
Haematologica (2015)

Fulltext@MSK | Save

Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: Updated safety and efficacy results of a phase 1 study (CA209-039)

Meeting Abstract

Armand, P.; Timmerman, J.; Lesokhin, A.; Halwani, A.; Millenson, M.; Schuster, S.; Gutierrez, M.; Scott, E.; Cattry, D.; Freeman, G.; more...
Haematologica (2015)

Fulltext@MSK | Save

Multivariate analysis of PFS from the AETHERA trial: A phase 3 study of brentuximab vedotin consolidation after autologous stem cell transplant for HL

Meeting Abstract

Walewski, J.; Nademanee, A.; Masszi, T.; Holowiecki, J.; Abidi, M.; Chen, A.; Stiff, P.; Viviani, S.; Bachanova, V.; Sweetenham, J.; more...
Haematologica (2015)

Fulltext@MSK | Save

Ibrutinib in previously treated patients with Waldenström's macroglobulinemia is highly active, produces durable responses, and is impacted by MYD88 and CXCR4 mutation status

Meeting Abstract

Treon, S.; Tripsas, C.; Meid, K.; Warren, D.; Varma, G.; Green, R.; Argyropoulos, K.; Yang, G.; Cao, Y.; Xu, L.; more...
Haematologica (2015)

Fulltext@MSK | Save

Heavy light chain ratio normalization allows identification of electrophoretic non-complete response patients with improved outcomes: A long term follow up update for BMT CTN 0102 correlative study

Meeting Abstract

D'Souza, A.; Pasquini, M.; Logan, B.; Giralt, S.; Krishnan, A.; Antin, J.; Howard, A.; Horowitz, M.; Goodman, S.; Laport, G.; more...
Haematologica (2015)

Fulltext@MSK | Save

A prior cancer diagnosis is not a risk factor for the developement of subsequent cancers in multiple myeloma patients

Meeting Abstract

Jonsdottir, G.; Lund, S. H.; Bjorkholm, M.; Hultcrantz, M.; Landgren, O.; Kristinsson, S. Y.
Haematologica (2015)

Fulltext@MSK | Save

Cardiovascular (CV) and pulmonary adverse events (AES) in patients (PTS) treated with BCR-ABL tyrosine kinase inhibitors (TKIS): Updated analysis from the FDA Adverse Event Reporting System (FAERS)

Meeting Abstract

Cortes, J.; Mauro, M.; Steegmann, J. L.; Saglio, G.; Soitkar, A.; Wallis, N.
Haematologica (2015)

Fulltext@MSK | Save

Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials

Meeting Abstract

Coutre, S.; Barrientos, J.; Brown, J.; de Vos, S.; Furman, R.; Keating, M.; O'Brien, S.; Pagel, J.; Sharman, J.; Zelenetz, A.; more...
Haematologica (2015)

Fulltext@MSK | Save

Ag-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies

Meeting Abstract

DiNardo, C.; Stein, E. M.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Fathi, A. T.; Flinn, I.; Frankel, A.; Levine, R. L.; Medeiros, B. C.; more...
Haematologica (2015)

Fulltext@MSK | Save

Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies

Meeting Abstract

de Botton, S.; Pollyea, D. A.; Stein, E. M.; DiNardo, C.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I.; Altman, J. K.; more...
Haematologica (2015)

Fulltext@MSK | Save

352 Results

People

Groups

Results (352)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract